Thank you.
I want to, again, thank all of the witnesses. All of this information has been really useful to inform further steps. I only wish that my Conservative colleagues had allowed us to get the most out of your testimony rather than theirs.
I certainly hear the concerns that industry representatives have brought forward, and these are really valid concerns. I just want to point out that, on cost recovery, my understanding is that consultations are still ongoing and that this is a draft proposal. I'm glad that we can get some of those concerns on record, including that Health Canada is still in the process of consulting with the industry.
I know I don't have a lot of time, but my questions will be for Ms. Hyland.
There have been many questions about the lack of ability to get the data that we need to have a good sense of the incidence of adverse effects. Under Vanessa's Law, my understanding is that this will add a mechanism to get better data on adverse effects. I wonder if you could comment on that aspect.